Status:
RECRUITING
A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
Lead Sponsor:
Peking University Third Hospital
Conditions:
Vitiligo
Eligibility:
All Genders
12+ years
Brief Summary
Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life. Current treatment for vitiligo primarily include topical med...
Detailed Description
Vitiligo is a common chronic autoimmune skin disease characterized by skin depigmentation, resulting in white patches that can occur on any part of the body and significantly impact patients' quality ...
Eligibility Criteria
Inclusion
- Age12 years or older, any gender;
- Signed"Informed Consent Form";
- Clinically diagnosed with non-segmental vitiligo;
- Vitiligo area less than 10% of body surface area;
- Agreed to discontinue all other vitiligo-related treatments from the screening visit until the final follow-up visit;
- Female subjects must not plan for pregnancy or oocyte donation from screening until 4 weeks after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include:
- Barrier methods: Condom or barrier cap (diaphragm or cervical cap);
- Intrauterine device (IUD) or intrauterine system (IUS);
- Surgical sterilization (bilateral oophorectomy with/without hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner;
- Other investigator-confirmed highly effective physical contraception.
Exclusion
- Allergy to ruxolitinib cream;
- Pregnant or lactating women;
- Any condition deemed inappropriate for study participation by the investigator.
Key Trial Info
Start Date :
December 8 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT07153666
Start Date
December 8 2025
End Date
December 31 2027
Last Update
January 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, China, 100191